bluebird bio Statistics

Total Valuation

bluebird bio has a market cap or net worth of $82.64 million. The enterprise value is $387.09 million.

Market Cap	82.64M
Enterprise Value	387.09M

Important Dates

The last earnings date was Thursday, November 14, 2024, before market open.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

bluebird bio has 9.72 million shares outstanding. The number of shares has increased by 72.23% in one year.

Current Share Class	9.72M
Shares Outstanding	9.72M
Shares Change (YoY)	+72.23%
Shares Change (QoQ)	+0.09%
Owned by Insiders (%)	0.47%
Owned by Institutions (%)	32.51%
Float	9.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.40
Forward PS	0.45
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	7.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.51

Current Ratio	0.51
Quick Ratio	0.29
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-15.24

Financial Efficiency

Return on equity (ROE) is -270.20% and return on invested capital (ROIC) is -44.45%.

Return on Equity (ROE)	-270.20%
Return on Assets (ROA)	-36.91%
Return on Capital (ROIC)	-44.45%
Revenue Per Employee	$141,653
Profits Per Employee	-$780,867
Employee Count	375
Asset Turnover	0.10
Inventory Turnover	2.10

Taxes

Income Tax	-83,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -82.51% in the last 52 weeks. The beta is 0.75, so bluebird bio's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	-82.51%
50-Day Moving Average	8.59
200-Day Moving Average	16.25
Relative Strength Index (RSI)	50.47
Average Volume (20 Days)	720,093

Short Selling Information

Short Interest	49.57M
Short Previous Month	43.64M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.53

Income Statement

In the last 12 months, bluebird bio had revenue of $53.12 million and -$292.83 million in losses. Loss per share was -$33.56.

Revenue	53.12M
Gross Profit	-25.66M
Operating Income	-318.48M
Pretax Income	-91.14M
Net Income	-292.83M
EBITDA	-262.27M
EBIT	-318.48M
Loss Per Share	-$33.56

Full Income Statement

Balance Sheet

The company has $70.65 million in cash and $375.10 million in debt, giving a net cash position of -$304.45 million or -$31.32 per share.

Cash & Cash Equivalents	70.65M
Total Debt	375.10M
Net Cash	-304.45M
Net Cash Per Share	-$31.32
Equity (Book Value)	-5.79M
Book Value Per Share	-0.60
Working Capital	-145.22M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$263.99 million and capital expenditures -$3.33 million, giving a free cash flow of -$267.32 million.

Operating Cash Flow	-263.99M
Capital Expenditures	-3.33M
Free Cash Flow	-267.32M
FCF Per Share	-$27.50

Full Cash Flow Statement

Margins

Gross Margin	-48.31%
Operating Margin	-599.54%
Pretax Margin	-551.41%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

bluebird bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-72.23%
Shareholder Yield	-72.23%
Earnings Yield	-354.34%
FCF Yield	-323.48%

Analyst Forecast

The average price target for bluebird bio is $49.14, which is 478.12% higher than the current price. The consensus rating is "Hold".

Price Target	$49.14
Price Target Difference	478.12%
Analyst Consensus	Hold
Analyst Count	9
Revenue Growth Forecast (5Y)	66.40%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Dec 13, 2024
Split Type	Reverse
Split Ratio	0.05:1

Scores

bluebird bio has an Altman Z-Score of -15.68 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-15.68
Piotroski F-Score	2